SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

12 ▪ Pernix has several potential inorganic growth opportunities that span a variety of indications and business models Bolt - On Focus Sales force 1 Pain (Non - Opioid) 5 Opportunistic / Generics 4 Neuroscience 2 Pain (Opioid) Existing Capabilities Leveraged Sector Backdrop Sales force CNS expertise from past Treximet ® promotion Existing portfolio & sales channel x Social / medical need x Attractive future growth prospects x Large player exits x Commonly prescribed despite negative perception x Broad, attractive indication x High deal / licensing activity 3 Pain Adjacent Sales force x Highlighted as pain regimen evolves x Greenspace areas with unmet needs Poised to Capitalize on BD Opportunities